List of Gene Editing/CRISPR Companies in Japan - 4

Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC. Our mission is to improve QOL of patients, their families, and HSC donors all over the world.

Chordia Therapeutics is a clinical-stage biotech company engaged in the research and development of novel therapies for cancers with high unmet medical needs. The Company was spun out from Takeda Pharmaceutical in November 2017.

Reborna Biosciences is a Japan based startup company developing RNA-targeting small molecule drugs for rare genetic diseases. Our proprietary screening method discovers orally available small molecules by reproducing the natural three-dimensional structure of RNA that exists in human body. Therefore, it can be expected to identify drug candidates having a higher extrapolation to clinical practice than the conventional screening method using artificially fragmented RNA (a form that does not exist in the body). We are convinced that this unique technology will contribute to the development of therapeutic drugs with higher efficacy and fewer side effects.